Improving Safe Use of Medications During Pregnancy: The Roles of Patients,Physicians,and Pharmacists

Abstract

Our study sought to explore the actual and potential roles of patients, physicians, and pharmacists, as well as their shared challenges and opportunities, in improving the safety of medication use during pregnancy. We conducted virtual focus groups with 48 women and in-depth interviews with nine physicians and five pharmacists. Qualitative analysis revealed that all three groups of participants reported “playing it safe,” the need for an engaged patient making informed decisions, challenges surrounding communication about pregnancy status, and a lack of patient-centric resources. Patients, physicians, and pharmacists are highly motivated to protect developing babies from potential harms of medication use during pregnancy while maintaining the patient’s health. Strategic messaging could maximize the effectiveness of these interactions by helping physicians discuss the benefits and risks of medication use during pregnancy, pharmacists screen for pregnancy and counsel on medication safety, and patients using medications to share pregnancy intentions with their providers pre-pregnancy.

Keywords

doctor–patient nurse–patient communication decision making patient education information seeking health pregnancy reproduction qualitative triangulation United States

Get full access to this article

View all access options for this article.

References

Adam

M. P.

Polifka

J. E.

Friedman

J. M.

(2011). Evolving knowledge of the teratogenicity of medications in human pregnancy. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 157, 175–182. doi:10.1002/ajmg.c.30313

Briggs

G. G.

Freeman

R. K.

Yaffe

S. J.

(2008). Drugs in pregnancy and lactation (8th ed.). Philadelphia: Lippincott Williams & Wilkins.

Crijns

Mantel-Teeuwisse

Bloemberg

Pinas

Straus

de Jong-Van den Berg

(2013). Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: A descriptive study. Expert Opinion on Drug Safety, 12, 29–38.

Damase-Michel

Christaud

Berrebi

Lacroix

Montastruc

J. L.

(2009). What do pregnant women know about non-steroidal anti-inflammatory drugs? Pharmacoepidemiology and Drug Safety, 18, 1034–1038.

Denzin

N. K.

(1978). Sociological methods. New York: McGraw-Hill.

Eisenberg

D. L.

Stika

Desai

Baker

Yost

K. J.

(2010). Providing contraception for women taking potentially teratogenic medications: A survey of internal medicine physicians’ knowledge, attitudes and barriers. Journal of General Internal Medicine, 25, 291–297. doi:10.1007/s11606-009-1215-2

Figueroa Gray

Hsu

Kiel

Dublin

. (2017). “It’s a very big burden on me”: Women’s experiences using insulin for gestational diabetes. Maternal and Child Health Journal, 21, 1678–1688. doi:10.1007/s10995-017-2261-8

Fisher

Rose

N. C.

Carey

J. C.

(2008). Principles and practice of teratology for the obstetrician. Clinical Obstetrics and Gynecology, 51, 106–118. doi:10.1097/GRF.0b013e318161d2c8

Goodwin

Rieder

M. J.

Matsui

(2007). Counseling regarding pregnancy-related drug exposures by family physicians in Ontario. Canadian Journal of Clinical Pharmacology/Journal Canadien De Pharmacologie Clinique, 14, e58–e69.

10.

Hammer

R. P.

Burton-Jeangros

(2013). Tensions around risks in pregnancy: A typology of women’s experiences of surveillance medicine. Social Science & Medicine, 93, 55–63.

11.

Krueger

R. A.

Casey

M. A.

(2000). Focus groups: A practical guide for applied research (3rd ed.). Thousand Oaks, CA: Sage.

12.

Kweder

S. L.

(2008). Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century. Birth Defects Research Part A: Clinical and Molecular Teratology, 82, 605–609. doi:10.1002/bdra.20500

13.

Lupattelli

Spigset

Twigg

M. J.

Zagorodnikova

Mardby

A. C.

Moretti

M. E.

. . . Nordeng

(2014). Medication use in pregnancy: A cross-sectional, multinational web-based study. American Journal of Obstetrics and Gynecology, 4(2), e004365.

14.

Lupton

(2012). “Precious cargo”: Foetal subjects, risk and reproductive citizenship. Critical Public Health, 22, 329–340.

15.

Mitchell

A. A.

Gilboa

S. M.

Werler

M. M.

Kelley

K. E.

Louik

Hernandez-Diaz

, . . . National Birth Defects Prevention Study. (2011). Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. American Journal of Obstetrics and Gynecology, 205(1), 51.e51–51.e58. doi:10.1016/j.ajog.2011.02.029

16.

Morgan

(1998). The focus group guidebook. Thousand Oaks, CA: Sage.

17.

Morgan

M. A.

Cragan

J. D.

Goldenberg

R. L.

Rasmussen

S. A.

Schulkin

(2010). Obstetrician-gynaecologist knowledge of and access to information about the risks of medication use during pregnancy. Journal of Maternal-fetal & Neonatal Medicine, 23, 1143–1150. doi:10.3109/14767051003653252

18.

Obican

Scialli

A. R.

(2011). Teratogenic exposures. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 157, 150–169.

19.

Riley

L. E.

Cahill

A. G.

Beigi

Savich

Saade

(2016). Improving safe and effective use of drugs in pregnancy and lactation: Workshop summary. American Journal of Perinatology, 34, 826–832. doi:10.1055/s-0037-1598070

20.

Samuel

Einarson

(2011). Medication management during pregnancy: Role of the pharmacist. International Journal of Clinical Pharmacy, 33, 882–885. doi:10.1007/s11096-011-9560-8

21.

Santucci

A. K.

Gold

M. A.

Akers

A. Y.

Borrero

Schwarz

E. B.

(2010). Women’s perspectives on counseling about risks for medication-induced birth defects. Birth Defects Research, Part A: Clinical and Molecular Teratology, 88, 64–69. doi:10.1002/bdra.20618

22.

Schwarz

E. B.

Maselli

Norton

Gonzales

(2005). Prescription of teratogenic medications in United States ambulatory practices. American Journal of Medicine, 118, 1240–1249.

23.

Schwarz

E. B.

Parisi

S. M.

Handler

S. M.

Koren

Cohen

E. D.

Shevchik

G. J.

. . . Fischer

G. S.

(2012). Clinical decision support to promote safe prescribing to women of reproductive age: A cluster-randomized trial. Journal of General Internal Medicine, 27, 831–838.

24.

Schwarz

E. B.

Parisi

S. M.

Handler

S. M.

Koren

Shevchik

Fischer

G. S.

(2013). Counseling about medication-induced birth defects with clinical decision support in primary care. Journal of Women’s Health, 22, 817–824.

25.

Schwarz

E. B.

Postlethwaite

D. A.

Hung

Y. Y.

Armstrong

M. A.

(2007). Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Annals of Internal Medicine, 147, 370–376.

26.

Schwarz

E. B.

Santucci

Borrero

Akers

A. Y.

Nikolajski

Gold

M. A.

(2009). Perspectives of primary care clinicians on teratogenic risk counseling. Birth Defects Research, Part A: Clinical and Molecular Teratology, 85, 858–863. doi:10.1002/bdra.20599

27.

U.S. Food & Drug Administration. (2016, March 23). Pregnancy and lactation labeling (drugs) final rule. Retrieved from http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm

28.

Wiley

K. E.

Cooper

S. C.

Wood

Leask

(2015). Understanding pregnant women’s attitudes and behavior toward influenza and pertussis vaccination. Qualitative Health Research, 25, 360–370.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB